Literature DB >> 1664967

Clinical signs and humoral immune response in horses following equine herpesvirus type-1 infection and their susceptibility to equine herpesvirus type-4 challenge.

A Stokes1, A H Corteyn, P K Murray.   

Abstract

A group of three horses was experimentally infected with equine herpesvirus type 1 (EHV-1) and showed clinical signs characterised by a biphasic febrile response, leucopenia and cell associated viraemia accompanied by virus shedding from the nasopharynx. A second exposure to the virus 18 days later resulted in the isolation of virus from the nasopharynx of one horse. This and a further group of three EHV-1 seropositive horses were subsequently infected with equine herpesvirus type 4 (EHV-4) 147 days after the initial EHV-1 infection and virus was shed from the nasopharynx in the absence of clinical disease. Following the first EHV-1 infection, virus specific immunoglobulin M (IgM) was present by day 5 and remained high until the second exposure at day 18 at which point levels decreased. In contrast, EHV-1 specific IgG, detected at day 6 peaked at day 18, after which time levels remained high. Virus neutralising antibodies and antibodies able to mediate antibody-dependent cellular cytotoxicity were present by day 10. The immune response to EHV-1 is discussed with reference to the disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1664967     DOI: 10.1016/0034-5288(91)90004-8

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  2 in total

1.  Equine herpesvirus type 4 UL56 and UL49.5 proteins downregulate cell surface major histocompatibility complex class I expression independently of each other.

Authors:  Abdelrahman Said; Walid Azab; Armando Damiani; Nikolaus Osterrieder
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Modulation of the serological response of specific pathogen-free (EHV-free) foals to EHV-1 by previous infection with EHV-4 or a TK-deletion mutant of EHV-1.

Authors:  D Tewari; J S Gibson; J D Slater; T O'Neill; D Hannant; G P Allen; H J Field
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.